ABSTRACT
Background: Metabolic syndrome is a group of abnormal laboratory and physical findings, such as dyslipidemia, hypertension, glucose intolerance, proinflammatory state, and prothrombotic state that results in a patient having significantly higher risk for atherosclerosis, cardiovascular disease, and overall mortality. There are slight differences between institutions in defining metabolic syndrome across the world. To achieve adequate management and treatment and decrease the risk of subsequent diseases, proper identification of symptomatic patients with metabolic syndrome is necessary
Aim: In this review, we aimed to study the pathophysiology behind the development of metabolic syndrome, and also to explore the approach to its management
Materials and Methods: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, January 2001, through February 2017. The following search terms were used: metabolic syndrome, pro-thrombotic state, pro-inflammatory state, diabetes mellitus, insulin resistance, obesity and cardiovascular mortality
Results: The major aspects of treatment include weight reduction by diet, medication, as well as bariatric surgery [in some cases], and managing hyperglycemia and insulin resistance with diet and medication
Conclusion: The most important intervention in managing patients with metabolic syndrome is lifestyle modification with improved diet and exercise. To achieve adequate treatment and decrease the risk of adverse outcomes, proper identification of symptomatic patients with metabolic syndrome is necessary
ABSTRACT
Introduction: Rheumatoid arthritis is considered one of the most common, and particularly attacks the joint causing significant individual and community burden, and present with articular as well as extra articular manifestation. Treatment modalities of rheumatoid arthritis have dramatically improved in recent years, significantly decreasing long-term auricular and extra-auricular complications
Aim of the work: this review was aimed to study the pathophysiology, clinical picture, and management of rheumatoid arthritis, with focus on the newer modalities.
Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, January 1985, through February 2017. The following search terms were used: rheumatoid arthritis, chronic inflammatory disorders, genetic of rheumatoid arthritis, management of rheumatoid arthritis, DMARD, biological agents
Conclusion: The newer modality of treatment must include disease-modifying antirheumatic drug [DMARDs] which must be started as early as possible. Combining DMARDs with corticosteroids will result in significantly better outcomes than monotherapy with any DMARD, and decrease long term morbidity associated with this condition